Axiom Uses New Text Messaging Services to Support Clinical Research
New York, NY
Axiom Accelerated Patient Recruitment (Axiom), is introducing innovative new text messaging (SMS) services.
“Mobile device outreach is the future of patient recruitment, due to the growth and convenience of this rapid-response medium,” said Jeff Clausing, Axiom Vice President.
According to NielsenMobile, a service of the Nielsen Company, a typical US mobile subscriber sends or receives an average of 357 text messages per month - 4,284 messages per year. Additionally, roughly 73% of mobile users already have a paid text messaging plan – a number that’s grown by 250% annually for the past two years.
Axiom is taking advantage of this growing trend by implementing text messaging services as part of its comprehensive patient recruitment and retention programs for clinical research studies.
“Clinical studies are an important way to advance research. In an era when healthcare is one of the nation’s leading topics of conversation, we believe clinical studies should be accessible to as many people as possible,” continued Julie Oimoen, Project Manager at Axiom. “We can best accomplish this by allowing potential participants to respond by using the medium with which they’re most comfortable. For many candidates in today’s world, that means text messaging.”
Axiom is able to identify pre-qualified audiences for numerous ailments and diseases ranging from asthma to adolescent schizophrenia. Text messages can be used to directly communicate with these pre-qualified audiences to gauge interest in participating in a clinical study that may help minimize symptoms or treat the disease. These services can also retain participants through support services like appointment reminders and treatment instructions. Text messaging provides a convenient, direct way to get in touch with pre-qualified potential patients quickly and efficiently.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
